

# Peter Hersey

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/248036/publications.pdf>

Version: 2024-02-01

78  
papers

13,837  
citations

76196

40  
h-index

79541

73  
g-index

83  
all docs

83  
docs citations

83  
times ranked

20482  
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and Tumor Responses with Lambrolizumab (Anti- $\text{PD-1}$ ) in Melanoma. <i>New England Journal of Medicine</i> , 2013, 369, 134-144.	13.9	3,128
2	Genomic Classification of Cutaneous Melanoma. <i>Cell</i> , 2015, 161, 1681-1696.	13.5	2,562
3	Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. <i>New England Journal of Medicine</i> , 2017, 376, 2211-2222.	13.9	1,087
4	Whole-genome landscapes of major melanoma subtypes. <i>Nature</i> , 2017, 545, 175-180.	13.7	1,068
5	Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1600.	3.8	857
6	Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. <i>Journal of Clinical Oncology</i> , 2016, 34, 1510-1517.	0.8	627
7	Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 2823-2830.	0.8	517
8	CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti- $\text{PD-1}$ Treatment. <i>Clinical Cancer Research</i> , 2018, 24, 3036-3045.	3.2	297
9	Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. <i>Clinical Cancer Research</i> , 2018, 24, 4960-4967.	3.2	222
10	Inducible but Not Constitutive Expression of PD-L1 in Human Melanoma Cells Is Dependent on Activation of NF- $\kappa$ B. <i>PLoS ONE</i> , 2015, 10, e0123410.	1.1	181
11	Microarray expression profiling in melanoma reveals a BRAF mutation signature. <i>Oncogene</i> , 2004, 23, 4060-4067.	2.6	169
12	Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. <i>Modern Pathology</i> , 2007, 20, 416-426.	2.9	169
13	Apoptosis Induction in Human Melanoma Cells by Inhibition of MEK Is Caspase-Independent and Mediated by the Bcl-2 Family Members PUMA, Bim, and Mcl-1. <i>Clinical Cancer Research</i> , 2007, 13, 4934-4942.	3.2	168
14	Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy. <i>Trends in Immunology</i> , 2019, 40, 328-344.	2.9	160
15	BRAF Mutation, NRAS Mutation, and the Absence of an Immune-Related Expressed Gene Profile Predict Poor Outcome in Patients with Stage III Melanoma. <i>Journal of Investigative Dermatology</i> , 2013, 133, 509-517.	0.3	156
16	Adjuvant Immunotherapy of Patients With High-Risk Melanoma Using Vaccinia Viral Lysates of Melanoma: Results of a Randomized Trial. <i>Journal of Clinical Oncology</i> , 2002, 20, 4181-4190.	0.8	144
17	MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , 2018, 19, 916-929.	5.1	131
18	Up-regulation of Mcl-1 Is Critical for Survival of Human Melanoma Cells upon Endoplasmic Reticulum Stress. <i>Cancer Research</i> , 2008, 68, 6708-6717.	0.4	129

#	ARTICLE	IF	CITATIONS
19	PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients. <i>Clinical Cancer Research</i> , 2015, 21, 3140-3148.	3.2	120
20	Modulation of NOXA and MCL-1 as a Strategy for Sensitizing Melanoma Cells to the BH3-Mimetic ABT-737. <i>Clinical Cancer Research</i> , 2012, 18, 783-795.	3.2	98
21	Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma. <i>Molecular Oncology</i> , 2014, 8, 544-554.	2.1	98
22	Randomized Trial of the Combination of Lomeguatrib and Temozolomide Compared With Temozolomide Alone in Chemotherapy Naive Patients With Metastatic Cutaneous Melanoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 2540-2545.	0.8	95
23	Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes. <i>Oncotarget</i> , 2015, 6, 27023-27036.	0.8	83
24	SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling. <i>Nature Communications</i> , 2018, 9, 3440.	5.8	80
25	Control of $\text{NF-}\kappa\text{B}$ activity in human melanoma by bromodomain and extra-terminal protein inhibitor BET151. <i>Pigment Cell and Melanoma Research</i> , 2014, 27, 1126-1137.	1.5	75
26	Factors related to the presentation of patients with thick primary melanomas. <i>Medical Journal of Australia</i> , 1991, 154, 583-587.	0.8	75
27	Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling. <i>Oncotarget</i> , 2015, 6, 21507-21521.	0.8	72
28	Marked Global DNA Hypomethylation Is Associated with Constitutive PD-L1 Expression in Melanoma. <i>IScience</i> , 2018, 4, 312-325.	1.9	69
29	Oncogenic Activation of MEK/ERK Primes Melanoma Cells for Adaptation to Endoplasmic Reticulum Stress. <i>Journal of Investigative Dermatology</i> , 2014, 134, 488-497.	0.3	66
30	Evidence that treatment with vaccinia melanoma cell lysates (VMCL) may improve survival of patients with stage II melanoma. <i>Cancer Immunology, Immunotherapy</i> , 1987, 25, 257-65.	2.0	62
31	Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. <i>European Journal of Cancer</i> , 2021, 144, 182-191.	1.3	57
32	Early Detection of Lung Cancer Risk Using Data Mining. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013, 14, 595-598.	0.5	56
33	The Epigenetic Regulator I-BET151 Induces BIM-Dependent Apoptosis and Cell Cycle Arrest of Human Melanoma Cells. <i>Journal of Investigative Dermatology</i> , 2014, 134, 2795-2805.	0.3	55
34	Distinct histone modifications denote early stress-induced drug tolerance in cancer. <i>Oncotarget</i> , 2018, 9, 8206-8222.	0.8	54
35	Emerging roles of H3K9me3, SETDB1 and SETDB2 in therapy-induced cellular reprogramming. <i>Clinical Epigenetics</i> , 2019, 11, 43.	1.8	53
36	Epigenetic modulation in cancer immunotherapy. <i>Current Opinion in Pharmacology</i> , 2017, 35, 48-56.	1.7	50

#	ARTICLE	IF	CITATIONS
37	Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 563-573.	2.0	50
38	HDAC inhibitors restore BRAF inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma. <i>International Journal of Cancer</i> , 2018, 142, 1926-1937.	2.3	48
39	EZH2: an emerging role in melanoma biology and strategies for targeted therapy. <i>Pigment Cell and Melanoma Research</i> , 2015, 28, 21-30.	1.5	47
40	EZH2 Cooperates with DNA Methylation to Downregulate Key Tumor Suppressors and IFN Gene Signatures in Melanoma. <i>Journal of Investigative Dermatology</i> , 2020, 140, 2442-2454.e5.	0.3	46
41	Somatic Copy Number Amplification and Hyperactivating Somatic Mutations of EZH2 Correlate With DNA Methylation and Drive Epigenetic Silencing of Genes Involved in Tumor Suppression and Immune Responses in Melanoma. <i>Neoplasia</i> , 2016, 18, 121-132.	2.3	43
42	Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma. <i>Modern Pathology</i> , 2015, 28, 884-894.	2.9	37
43	EZH2 as a mediator of treatment resistance in melanoma. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 500-507.	1.5	37
44	Treatment combinations targeting apoptosis to improve immunotherapy of melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 1749-1759.	2.0	32
45	Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy. <i>Cancers</i> , 2015, 7, 1959-1982.	1.7	32
46	Contrasting Effects of Nutlin-3 on TRAIL- and Docetaxel-Induced Apoptosis Due to Upregulation of TRAIL-R2 and Mcl-1 in Human Melanoma Cells. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 3363-3374.	1.9	30
47	Evidence for upregulation of Bim and the splicing factor SRp55 in melanoma cells from patients treated with selective BRAF inhibitors. <i>Melanoma Research</i> , 2012, 22, 244-251.	0.6	30
48	OBATOCLAX and ABT-737 Induce ER Stress Responses in Human Melanoma Cells that Limit Induction of Apoptosis. <i>PLoS ONE</i> , 2013, 8, e84073.	1.1	29
49	Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma. , 2020, 8, e000410.		21
50	Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients. <i>Frontiers in Immunology</i> , 2020, 11, 372.	2.2	20
51	A Focus on PD-L1 in Human Melanoma. <i>Clinical Cancer Research</i> , 2013, 19, 514-516.	3.2	17
52	Acetylsalicylic Acid Governs the Effect of Sorafenib in <i>RAS</i> -Mutant Cancers. <i>Clinical Cancer Research</i> , 2018, 24, 1090-1102.	3.2	16
53	Magnolol induces cell death through PI3K/Akt-mediated epigenetic modifications boosting treatment of <i>BRAF</i> and <i>NRAS</i> -mutant melanoma. <i>Cancer Medicine</i> , 2019, 8, 1186-1196.	1.3	16
54	Study of the Female Sex Survival Advantage in Melanoma—A Focus on X-Linked Epigenetic Regulators and Immune Responses in Two Cohorts. <i>Cancers</i> , 2020, 12, 2082.	1.7	16

#	ARTICLE	IF	CITATIONS
55	Co-targeting bromodomain and extra-terminal proteins and MCL1 induces synergistic cell death in melanoma. <i>International Journal of Cancer</i> , 2020, 147, 2176-2189.	2.3	16
56	Do innate killing mechanisms activated by inflammasomes have a role in treating melanoma?. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 660-670.	1.5	14
57	Lysine Demethylases: Promising Drug Targets in Melanoma and Other Cancers. <i>Frontiers in Genetics</i> , 2021, 12, 680633.	1.1	14
58	A Th1/IFN $\gamma$ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1725-1735.	3.2	13
59	Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006. <i>European Journal of Cancer</i> , 2021, 157, 391-402.	1.3	13
60	Commonly integrated epigenetic modifications of differentially expressed genes lead to adaptive resistance in cancer. <i>Epigenomics</i> , 2019, 11, 732-737.	1.0	11
61	Repurposing Melanoma Chemotherapy to Activate Inflammasomes in the Treatment of BRAF/MAPK Inhibitor Resistant Melanoma. <i>Journal of Investigative Dermatology</i> , 2022, 142, 1444-1455.e10.	0.3	11
62	Epigenetic inhibitors eliminate senescent melanoma BRAFV600E cells that survive long-term BRAF inhibition. <i>International Journal of Oncology</i> , 2020, 56, 1429-1441.	1.4	10
63	TP53 Codon 72 Polymorphisms and Lung Cancer Risk in the Bangladeshi Population. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 16, 3493-3498.	0.5	10
64	Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma. <i>Future Oncology</i> , 2015, 11, 133-140.	1.1	9
65	A preliminary evaluation of cytotoxicity, antihyperglycemic and antinociceptive activity of Polygonum hydropiper L. ethanolic leaf extract. <i>Clinical Phytoscience</i> , 2017, 2, .	0.8	9
66	DPP9: Comprehensive In Silico Analyses of Loss of Function Gene Variants and Associated Gene Expression Signatures in Human Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 1637.	1.7	9
67	Transcriptional Reprogramming and Constitutive PD-L1 Expression in Melanoma Are Associated with Dedifferentiation and Activation of Interferon and Tumour Necrosis Factor Signalling Pathways. <i>Cancers</i> , 2021, 13, 4250.	1.7	9
68	A Combination of Epigenetic BET and CDK9 Inhibitors for Treatment of Human Melanoma. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2238-2249.e12.	0.3	7
69	Nicotinamide Inhibits T Cell Exhaustion and Increases Differentiation of CD8 Effector T Cells. <i>Cancers</i> , 2022, 14, 323.	1.7	6
70	Sex bias of females in survival from cancer and infections. Is X the answer?. <i>British Journal of Cancer</i> , 2021, 124, 1184-1186.	2.9	5
71	Score Based Risk Assessment of Lung Cancer and its Evaluation for Bangladeshi People. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 7021-7027.	0.5	5
72	Shedding light on dabrafenib-induced fevers in patients with melanoma. <i>Lancet Oncology</i> , The, 2019, 20, 1637-1638.	5.1	2

#	ARTICLE	IF	CITATIONS
73	Dual Targeting with EZH2 Inhibitor and STING Agonist to Treat Melanoma. Journal of Investigative Dermatology, 2022, 142, 1004-1006.	0.3	2
74	Associations between DPP9 expression, survival and gene expression signature in human hepatocellular carcinoma: Comprehensive in silico analyses. FASEB Journal, 2021, 35, .	0.2	1
75	Abstract B34: Global histone modifications define early stress induced drug tolerance in cancer. , 2016, , .		0
76	Abstract 5833: Escape form adaptive drug tolerance through OGT and TET1 mediated H3K4me3 remodeling in MAPKi resistant melanoma. , 2018, , .		0
77	Abstract LB-177: BET and CDK9 protein inhibitors: Novel epigenetic therapy to synergistically kill human melanoma cells. , 2020, , .		0
78	Re: Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers. European Journal of Cancer, 2022, 162, 241-242.	1.3	0